THERAPEUTIC FOCUS - GSNOR Inhibition to Stabilize & Improve Mutant CFTR Processing
Steven Shoemaker, MD, reviews how cavosonstat represents a safe and effective option for patients with CF with at least one copy of the F508del-CFTR mutation; and that when used with correctors and potentiators, improves patient outcomes including lung function.
EXECUTIVE INTERVIEW - AmerisourceBergen: Partnering With Orphan Product Manufacturers to Drive Commercialization Success
Amy Grogg, Senior Vice President of Strategy and Commercialization at AmerisourceBergen Specialty Group provides her perspective on the barriers orphan drug manufacturers face and the solutions available to them through strategic partnerships with distributors.
PATIENT-CENTRIC TECHNOLOGY - How Technology Can Impact Patient Adherence: Increasing Patient Engagement & Education to Save the Healthcare Industry Billions
Andrew W. Dunning provides several examples of technologies that specifically cater to pharmaceutical brands that want to leverage a patient-centric marketing strategy to increase their market share and boost patient adherence rates.
SPECIAL FEATURE - Bioavailability & Solubility: New Approaches to Enhance Drug Performance
Contributor Cindy H. Dubin highlights many of the latest techniques to enhance bioavailability and solubility, how to determine the right technique for your compound, and how some companies are realizing faster time to market as a result.
SPECIAL FEATURE - Analytical Testing: Market Drivers, Growing Demand & Client Needs
Contributor Cindy H. Dubin spoke with several testing providers to find out what services they offer, trends they identify, and how they have specifically addressed clients’ needs throughout the past year.
FORMULATION DEVELOPMENT - Optimizing the Spray-Drying Parameters for a Formulation of Nanoparticles-In-Microparticles System of Acetazolamide
Parijat Pandey, MPharm, and Harish Dureja, PhD, examine the consequence of spray-drying parameters that are inlet temperature and feed rpm on entrapment efficiency, loading capacity, percentage yield, and particle size.
ORALLY DISINTEGRATING TABLETS - Patient-Centric Dose Design, Developments in Orally Disintegrating Tablets
Leon Grother, MS, and Mathias Bayru, MS, MBA, indicate recent developments in ODT technology have widened the range of actives that can be formulated and product types that are possible. In particular, the promise of formulating biologics and ODT vaccines is hugely exciting.
ADVANCED DELIVERY DEVICES - Disruptive Delivery Technology Partnerships Are Key to Pharmaceutical Life Cycle Management
Michael D. Hooven, MSME, believes in the challenge to deliver innovative therapies that address unmet patient needs while delivering profitable growth, and the industry is responding by embracing disruptive technology that can concurrently help on both fronts and also speed time to market for pharmaceutical products and services.
BIODEGRADABLE FIBERS - Enabling Controlled Pharmaceutical & Biologic Delivery for Next-Generation Medical Applications
Kevin Nelson, PhD, discusses how wet-extruded fiber eliminates the traditional limitations of pharmaceuticals and biologics that may be incorporated into implantable medical devices with melt extrusion or electrospun fibers, microspheres, or nanoparticles.
EXECUTIVE INTERVIEW - Avista Pharma Solutions: Experience, Responsiveness & Expanded Capacity Driving Growth
Patrick Walsh, CEO of Avista Pharma Solutions, talks about his company’s range of capabilities and what is driving growth in this dynamic industry.
COMBINATION PRODUCTS - 6 Guidelines to Follow When Developing Combination Products
Winston Brown explains how companies can reduce the risk and impact that regulatory uncertainty can play by, in advance of pursuing development, understanding the regulatory landscape and then developing a regulatory compliance strategy that is appropriate and suitable for the combination product as a system.
EXECUTIVE INTERVIEW - Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates
Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.
CNS DELIVERY - Bypassing the BBB: Drug Delivery From the Olfactory Mucosa to the CNS
T.R. Shantha, MD, PhD, FACA, explores and explains how therapeutic and non- therapeutic agents can reach the brain, bypassing through the formidable BBB based on the unique microanatomic and physiologic characteristics of the nasal olfactory mucosal route and its CNS connections that allow transportation directly into the CNS.
Avomeen Recapitalizes to Achieve Next Growth Plan Objective
In an effort to foster growth and reinforce its infrastructure, Avomeen Analytical Services, a fast growing full-service independent analytical and chemical testing laboratory based in…
Avomeen Recapitalizes to Achieve Next Growth Plan Objective
In an effort to foster growth and reinforce its infrastructure, Avomeen Analytical Services, a fast growing full-service independent analytical and chemical testing laboratory based in…
Leading Developer of Multi-Layer Oral Thin Film Completes Going Public Transaction
CURE Pharmaceutical, a pre-eminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, recently announced the…
Metrics: Stability Storage Facility Q&A
Metrics Contract Services recently announced it is investing $3.5 million to build a dedicated, 15,000-square-foot stability storage facility that will triple the organization’s current storage…
PROTEIN THERAPEUTICS MARKET - Technology Advances Spur Market Growth of Protein Therapies
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
EXTERNAL DELIVERY - P.U.M.P. IT UP
John A. Bermingham, asks if you have ever been really hungry? He doesn’t mean the hunger you experience in the morning or just before dinner. He’s talking about major league hunger!
PLATFORM TECHNOLOGY - The 3DNA® Platform for Targeted Drug Delivery
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
